Inventor
POIROT LAURENT
FR38 patents
⚠️ This page may combine multiple inventors who share the name “POIROT LAURENT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELLECTIS
36 patentsUS9855297B2Jan 2, 2018
Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
CELLECTIS50 citations97
US9890393B2Feb 13, 2018
Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
CELLECTIS38 citations94
US10584352B2Mar 10, 2020
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
CELLECTIS21 citations93
US10426795B2Oct 1, 2019
Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells
CELLECTIS8 citations92
US10286007B2May 14, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS12 citations92
US10836998B2Nov 17, 2020
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CELLECTIS5 citations84
US10239948B2Mar 26, 2019
Method of engineering multi-input signal sensitive T cell for immunotherapy
CELLECTIS16 citations84
US10196608B2Feb 5, 2019
Method for in situ inhibition of regulatory T cells
CELLECTIS8 citations84
US11274316B2Mar 15, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US10870864B2Dec 22, 2020
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
CELLECTIS4 citations83
US10517896B2Dec 31, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US10363270B2Jul 30, 2019
Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy
CELLECTIS6 citations83
US10472613B2Nov 12, 2019
Method for modulating car-induced immune cells activity
CELLECTIS6 citations73
US12577581B2Mar 17, 2026
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11891614B2Feb 6, 2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
CELLECTIS1 citations72
US11414674B2Aug 16, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11304975B2Apr 19, 2022
Methods for engineering allogeneic and highly active t cell for immunotherapy
CELLECTIS4 citations72
US11186824B2Nov 30, 2021
Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
CELLECTIS4 citations72
US11959091B2Apr 16, 2024
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
CELLECTIS0 citations62
US11692169B2Jul 4, 2023
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CELLECTIS0 citations62
US11365430B2Jun 21, 2022
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
CELLECTIS0 citations62
US11311575B2Apr 26, 2022
Methods for engineering highly active T cell for immunotherapy
CELLECTIS1 citations62
US10988542B2Apr 27, 2021
Chimeric antigen receptors with integrated controllable functions
CELLECTIS0 citations62
US12391933B2Aug 19, 2025
Targeted gene insertion for improved immune cells therapy
CELLECTIS0 citations61
US12252699B2Mar 18, 2025
Method for generating t-cells compatible for allogenic transplantation
CELLECTIS0 citations61
US12209125B2Jan 28, 2025
Targeted gene integration of NK inhibitors genes for improved immune cells therapy
CELLECTIS0 citations61
US11873511B2Jan 16, 2024
Targeted gene insertion for improved immune cells therapy
CELLECTIS0 citations61
US11820996B2Nov 21, 2023
Method for generating T-cells compatible for allogenic transplantation
CELLECTIS0 citations61
US11903968B2Feb 20, 2024
Engineered immune cells resistant to tumor microenvironment
CELLECTIS0 citations59
US12221478B2Feb 11, 2025
Targeted gene integration of CRS inhibitor genes for improved immune cells therapy
CELLECTIS0 citations58
US12171820B2Dec 24, 2024
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
CELLECTIS0 citations56
US11603539B2Mar 14, 2023
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
CELLECTIS0 citations54
US10894093B2Jan 19, 2021
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
CELLECTIS0 citations52
US12365733B2Jul 22, 2025
Method for improving production of car T cells
CELLECTIS0 citations47
US12144825B2Nov 19, 2024
Cellular immunotherapy for repetitive administration
CELLECTIS0 citations46
US10765728B2Sep 8, 2020
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
CELLECTIS0 citations46